deltatrials
Completed PHASE3 NCT00528567

BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer

An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in Triple Negative Breast Cancer.

Sponsor: Hoffmann-La Roche

Conditions Breast Cancer
Interventions Bevacizumab Standard adjuvant chemotherapy
Updated 7 times since 2017 Last updated: Aug 5, 2015 Started: Dec 31, 2007 Primary completion: Feb 29, 2012 Completion: Jun 30, 2014

This PHASE3 trial investigates Breast Cancer and is currently completed. Hoffmann-La Roche leads this study, which shows 7 recorded versions since 2007 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

7 versions recorded

  1. Dec 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2025 — Dec 2025 [monthly]

    Completed PHASE3

  3. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  5. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  2. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Dec 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Hoffmann-La Roche
Data source: Hoffmann-La Roche

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aarau, Switzerland, Abingdon, United States, Aichi, Japan, Angers, France, Atlanta, United States, Auckland, New Zealand, Augusta, United States, Austin, United States, Aviano, Italy, Bakersfield, United States and 340 more location s